Cwerman-Thibault Hélène, Lechauve Christophe, Augustin Sébastien, Roussel Delphine, Reboussin Élodie, Mohammad Ammara, Degardin-Chicaud Julie, Simonutti Manuel, Liang Hong, Brignole-Baudouin Françoise, Maron Anne, Debeir Thomas, Corral-Debrinski Marisol
Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, 75012 Paris, France.
PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, 75019 Paris, France.
Mol Ther Methods Clin Dev. 2017 Apr 27;5:200-220. doi: 10.1016/j.omtm.2017.04.008. eCollection 2017 Jun 16.
Mitochondrial dysfunction is responsible for hereditary optic neuropathies. We wished to determine whether preserving mitochondrial bioenergetics could prevent optic neuropathy in a reliable model of glaucoma. DBA/2J mice exhibit elevated intraocular pressure, progressive degeneration of their retinal ganglion cells, and optic neuropathy that resembles glaucoma. We established that glaucoma in these mice is directly associated with mitochondrial dysfunction: respiratory chain activity was compromised in optic nerves 5 months before neuronal loss began, and the amounts of some mitochondrial proteins were reduced in retinas of glaucomatous mice. One of these proteins is neuroglobin, which has a neuroprotective function. Therefore, we investigated whether gene therapy aimed at restoring neuroglobin levels in the retina via ocular administration of an adeno-associated viral vector could reduce neuronal degeneration. The approach of treating 2-month-old mice impeded glaucoma development: few neurons died and respiratory chain activity and visual cortex activity were comparable to those in young, asymptomatic mice. When the treatment was performed in 8-month-old mice, the surviving neurons acquired new morphologic and functional properties, leading to the preservation of visual cortex activity and respiratory chain activity. The beneficial effects of neuroglobin in DBA/2J retinas confirm this protein to be a promising candidate for treating glaucoma.
线粒体功能障碍是遗传性视神经病变的病因。我们希望确定在可靠的青光眼模型中,维持线粒体生物能量学是否能够预防视神经病变。DBA/2J小鼠表现出眼压升高、视网膜神经节细胞进行性退化以及类似青光眼的视神经病变。我们证实这些小鼠的青光眼与线粒体功能障碍直接相关:在神经元损失开始前5个月,视神经中的呼吸链活性受损,青光眼小鼠视网膜中的一些线粒体蛋白含量降低。其中一种蛋白是具有神经保护功能的神经珠蛋白。因此,我们研究了通过眼内注射腺相关病毒载体来恢复视网膜中神经珠蛋白水平的基因治疗是否能够减少神经元退化。治疗2月龄小鼠的方法阻碍了青光眼的发展:很少有神经元死亡,呼吸链活性和视觉皮层活性与年轻无症状小鼠相当。当对8月龄小鼠进行治疗时,存活的神经元获得了新的形态和功能特性,从而维持了视觉皮层活性和呼吸链活性。神经珠蛋白在DBA/2J视网膜中的有益作用证实该蛋白是治疗青光眼的一个有前景的候选药物。